Sign Out
XIGDUO XR (dapagliflozin and metformin HCl extended-release) is indicated as substitution therapy for treatment of type 2 diabetes mellitus in adjunct to diet and exercise to improve glycemic control in adults patients already controlled with dapagliflozin and metformin XR given concurrently at the same dose level.
For study results with respect to combination of therapies, effects on glycaemic control and cardiovascular events, and the populations studied, see Precautions, Adverse Reactions and Pharmacology: Pharmacodynamics under Actions.
Lanjutkan dengan Google